GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (STU:7NS0) » Definitions » NonCurrent Deferred Liabilities

Palisade Bio (STU:7NS0) NonCurrent Deferred Liabilities : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Palisade Bio's non-current deferred liabilities for the quarter that ended in Mar. 2024 was €0.00 Mil.

Palisade Bio NonCurrent Deferred Liabilities Historical Data

The historical data trend for Palisade Bio's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio NonCurrent Deferred Liabilities Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
- - - -

Palisade Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Palisade Bio NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Palisade Bio's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Palisade Bio (STU:7NS0) Business Description

Industry
Traded in Other Exchanges
Address
5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Palisade Bio (STU:7NS0) Headlines

No Headlines